Allogene Therapeutics Announces The Publication Of Pre-Cli...

Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical Models
Dual CD19/CD70 CAR T Cells Rapidly Eliminated B and T Cells in Systemic Lupus Erythematosus (SLE) Models, Halting Autoantibody Production
Phase 1 RESOLUTION Dose Escalation Rheumatology Basket Trial Actively Enrolling; Initial Data from First Dose Level Expected June 2026 with an Additional Clinical Update Planned for Year-End
ALLO-329 Previously Received Three FDA Fast Track Designations for the Treatment of Adult Patients with Lupus, Myositis and Scleroderma

Allogene Therapeutics Announces The Publication Of Pre-Clinical Data For ALLO-329, An Investigational Allogeneic CAR T Product Developed Specifically For Autoimmune Diseases, In The Journal &#39;Nature Communications&#39;